What people are reporting about NAD+ infusions

The conversation about NAD+ infusions in online health and longevity communities is extensive, specific, and unusually consistent in some of its descriptions. Across r/Nootropics, r/longevity, r/peptides, biohacker forums, anti-aging clinic patient communities, and health optimization Discords, people have been sharing their experiences with intravenous NAD+ for several years. The threads span a wide range of intentions and outcomes, but certain motifs appear with enough regularity that they're worth examining as a window into what the public conversation actually looks like — what draws people in, what they report experiencing, and what concerns get raised alongside the enthusiasm.

Before going further, the nature of this data should be stated plainly. Online forums have a strong positivity bias. The people who return to report that a protocol did something useful are overrepresented relative to those who had no effect or a negative experience and simply moved on. The people most likely to post detailed experiences are those with the most dramatic responses — either very good or very bad. Most people's reactions, which are probably somewhere in the middle, are underrepresented in what shows up in threads. What follows is a synthesis of reported experiences, not a clinical survey. The patterns are real as patterns of what's being said. They are not evidence of what these compounds do.

The single most reported phenomenon across NAD+ infusion discussions is the sensation during the infusion itself. It comes up in nearly every substantive thread and is described with enough consistency to be striking. People describe a warmth — starting in the chest or face and spreading through the body — that intensifies as the infusion rate increases. Some describe it as an uncomfortable tightness in the chest or throat, a pressure that is distinct from pain but that some find distressing enough to ask the nurse to slow the drip. Others describe it as a pulsing warmth that is intense but not unpleasant once they know to expect it. Heart palpitation-adjacent sensations are commonly mentioned — a flutter or awareness of heartbeat that can be surprising, particularly on a first infusion. Nearly everyone who reports this experience also notes that it resolves when the drip is slowed and disappears when the infusion ends.

The posts from first-time recipients often follow a pattern: they report being unprepared for the intensity of the sensation, that no one fully briefed them, and that knowing what to expect would have made the experience much less alarming. The posts from experienced recipients mostly describe having developed a relationship with the sensation — slowing the drip preemptively as it starts, finding a rate at which the warmth is present but manageable, treating it as a signal to adjust rather than a symptom of something wrong. Several experienced users report that subsequent infusions feel less intense than the first, which they attribute variously to familiarity, tolerance, or improved technique by their provider.

The acute post-infusion period — the hours immediately following the session — is described with similarly consistent language. Fatigue. Sometimes described as a crash, sometimes as a deep tiredness that is different from ordinary exhaustion in texture — flatter, heavier, calmer. Some people go home and sleep. Some feel mentally drained in a way that feels organic, like having done strenuous cognitive work. The community posts frame this mostly as expected and temporary, as part of the protocol rather than a concerning sign, though the posts also acknowledge that people who weren't warned about this found it unsettling. Reports of nausea during or immediately after the infusion appear occasionally, again more commonly associated with faster infusion rates.

Then — and this is where the community reports become most consistent and most enthusiastic — comes the days following. The post-infusion energy reports in these communities are the central reason people share their experiences. They describe energy that is qualitatively different from caffeine or stimulant alertness: not wired, not racing, but present and clean. Words like "clarity," "brightness," "sharpness," and "presence" appear frequently. People describe tasks that had felt cognitively heavy becoming lighter. They describe a quality of wakefulness that feels unusual — not hyperactivated but fully on, more available to the moment than they typically are. The duration of this state is commonly described as two to five days after a single infusion, with some people reporting effects lasting closer to a week or more. A smaller number report more modest effects, and some report no perceptible change — which, given the positivity bias in what gets posted, is worth noting as an indication that non-response is real.

Physical energy is described alongside cognitive clarity, though less consistently. Some people report that workouts feel better in the days following an infusion. Others focus almost entirely on the cognitive dimension. Recovery from exercise is mentioned in the context of both IV NAD+ and subcutaneous microdosing, with some community members describing reduced post-exercise soreness and faster return to baseline, though these reports are anecdotal and the recovery context mixes with other supplements and practices in ways that make attribution difficult.

The comparison between IV and subcutaneous microdosing comes up frequently in more experienced corners of the community. People who have tried both generally describe IV as more intense — the sensation during, the fatigue immediately after, and the clarity in the following days are all more pronounced. Subcutaneous, by contrast, is described as milder across all dimensions: less sensation at the injection site and systemically, no post-injection crash comparable to IV, and a more subtle, ongoing quality of effect rather than a peak-and-taper pattern. Some community members prefer the subcutaneous approach precisely because it's gentler and more sustainable as a frequent protocol. Others feel that subcutaneous doesn't replicate the specific clarity they get from IV and use subQ only as a maintenance strategy between IV sessions.

The dose ranges discussed in these communities are wide. For IV, the discussion centers around 500 mg as a lower-end therapeutic dose and 1000 to 1500 mg as a higher-end dose, with some clinic protocols using 750 mg as a standard. For subcutaneous microdosing, discussions reference doses as low as 25 mg and as high as 100 mg per injection, with various frequency suggestions. Some community members describe daily subcutaneous dosing at 50 mg; others do twice-weekly protocols. The lack of standardization in these approaches is acknowledged in the community itself, with frequent statements that protocols vary widely by provider and that there is no established standard for frequency or dose.

The cost conversation is one of the more frequently occurring practical discussions. Single IV NAD+ infusions at clinics are consistently reported in the $400 to $1000 range depending on dose and location, with higher-end wellness clinics at the top of that range and some telehealth-adjacent compounding pharmacy setups described as more accessible. People who have done multiple infusions, particularly through loading protocols of three to five consecutive sessions, describe total initial costs in the thousands of dollars. This creates a barrier that community members discuss explicitly — there is awareness that the people who can access IV NAD+ protocols represent a narrow demographic, and threads occasionally engage with whether the outcomes justify the cost differential versus oral supplementation.

The cycling debate is present in the community as a real and unresolved discussion. Some members report doing quarterly IV sessions with daily oral NMN or NR between them, treating the IV as a periodic reset and the oral supplementation as maintenance. Others report doing IV infusions monthly. Some are skeptical that cycling matters and do infusions whenever their schedule and budget allow. The community has not arrived at consensus, and the lack of clinical trial data on infusion frequency means the discussion is largely based on experience and provider recommendation rather than evidence-based protocols.

Stacking practices — combining IV or subQ NAD+ with other supplements — are extensively discussed. Oral NMN or NR alongside IV NAD+ as a maintenance strategy is common. B vitamins, particularly B3 (niacin or niacinamide) and the other B vitamins, appear frequently in stacking discussions, partly because many IV NAD+ formulations include a B-complex component and partly because community members believe the B vitamins support the broader NAD+ synthesis pathway. Magnesium is mentioned as an adjunct to reduce the cardiovascular sensations during infusion. Resveratrol and pterostilbene — the sirtuin-activating polyphenols that were part of the early Sinclair protocol — appear in many stacks alongside NAD+ precursors, reflecting the community's engagement with the sirtuin biology that underlies the broader NAD+ story.

The applications that draw people to these protocols are varied. Cognitive performance and mental clarity are the most commonly cited motivation. Energy and fatigue, particularly in the context of chronic fatigue or post-viral fatigue states, appear frequently — these communities have a notable contingent of people who describe using NAD+ infusions in the context of long COVID or post-infectious syndromes, sometimes with reported benefit, though this is an area where the evidence base is extremely limited and community reports are an unreliable guide to what might help a clinical condition. Anti-aging and longevity motivation is present but not as dominant in community discussions as the cognitive and energy motivations, perhaps because longevity outcomes are not observable in the way that subjective energy and clarity are.

Adverse experience reports do appear in these communities, and they're worth acknowledging alongside the positive accounts. Beyond the expected intensity and post-infusion fatigue, people occasionally report headache, nausea, or an unusual emotional experience during or after infusion — some describe a kind of emotional rawness or heightened mood in the period following that they didn't expect. These reports are less common than the positive experience reports and don't indicate a pattern of serious harm in the community discussions, but they point to the fact that individual responses vary and that the absence of a robust clinical adverse event database for compounded NAD+ infusions means that self-reported community experience is filling a gap.

The community discussion around NAD+ infusions reflects genuine interest in a biologically serious question. The people having these conversations are, for the most part, engaged and thoughtful rather than credulous, and the threads often include skeptical voices, requests for sourcing, and acknowledgment that the evidence base is incomplete. What the community is doing — in the absence of accessible clinical trial participation or clear prescribing guidelines — is generating a collective experiential record through self-experiment and shared report. That record is interesting as a picture of what people experience. It is not evidence of safety, efficacy, or appropriate protocols. Compounded NAD+ infusion protocols are not FDA-approved, the pharmacokinetics are not fully characterized in human trials, and individual variation in response is substantial. This is a conversation worth having with a qualified prescribing provider — not one to navigate through forum posts alone.